In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1.0 billion bridge facility with Goldman Sachs Bank USA. Illumina is Grail’s largest shareholder, holding a 14.5% stake. In connection with the transaction, GRAIL stockholders will also receive contingent value rights, which will entitle holders to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. ILMN, This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome GRAIL back to Illumina to help transform cancer care using genomics and our NGS platform,” said Francis deSouza, Illumina’s President and Chief Executive Officer. Illumina expects to close the transaction in the second half of 2021. kbirmingham@illumina.com, Matt Burns While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Additional … The cash consideration to GRAIL stockholders excluding Illumina of approximately $3.1 billion is expected to be funded using balance sheet cash of both Illumina and GRAIL plus up to $1 billion in capital raised through either a debt or equity issuance. Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. Revenue above $1 billion each year would be subject to a 9% contingent payment right during this same period. Shares of Illumina (NASDAQ:ILMN) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. If you experience any issues with this process, please contact us for further assistance. (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. And Grail is backed by some big names like Bill Gates, Jeff Bezos, and Google Ventures. You can sign up for additional alert options at any time. You must click the activation link in order to complete your subscription. SPX, After submitting your request, you will receive an activation email to the requested email address. Jacquie Ross, CFA has rallied 13.1% and the S&P 500 The two companies have a decade-long supply and commercialization agreement in place that involves Grail … Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov, through Illumina’s Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Well, Grail’s initial public offering (IPO) isn’t going to happen. Multi-cancer early detection is better for patients, their physicians, and payors. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. That’s more than double Grail’s last known valuation. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Shares of Illumina Inc. ILMN, +0.20% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to buy cancer-detection company Grail … Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Number: (866) 211-4597, or the International Dial-In Number: (647) 689-6853 outside North America, both with passcode 2245817. Earlier this week, Exact Sciences agreed to buy Thrive, one of Grail’s competitors developing a cancer-detecting liquid biopsy sector, for $2.15 billion. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. To understand this deal, recent events and the investment thesis, I go back to the start of 2017 when I … The news came less than two weeks after GRAIL filed for an IPO. Grail stockholders will get $3.5 billion in cash and $4.5 billion in shares in Illumina stock. Perhaps with that misadventure in mind, not to mention Grail's apparently high price tag, traders sent Illumina stock down by nearly 8.5% on Wednesday -- … Launching a New Era in + The Wall Street Journal reported earlier that an announcement of the deal, in which Illumina pays $7.1 billion for the part of Grail it doesn't already own, would be announced Monday. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina is rumoured to be in talks with oncology testing company Grail over a potential $8bn bid. Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. That’s more than double Grail’s last known valuation. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders.”, “Cancer is one of society’s most significant challenges, with most cancer being detected too late,” said Hans Bishop, Chief Executive Officer of GRAIL. The early stage company was valued at … Upon closing of the transaction, current Illumina stockholders are expected to own approximately 93% of the combined company, while GRAIL stockholders are expected to own approximately 7% based on the mid-point of the collar. has gained 2.8%. GRAIL was founded by Illumina in 2016 and was spun out as a standalone company, powered by Illumina’s NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests. So … The stock has dropped 10.9% year to date through Friday, while the iShares Nasdaq Biotechnology ETF Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion in cash and stock, the companies announced Monday. The deal confirmed … Illumina founded Grail in 2016 and spun it off into a separate company. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal Illumina will buy the remaining stake in Jeff Bezos-backed gene-sequencing company Grail that it doesn’t already own for $8 billion in cash and stock. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Grail was founded by Illumina, divested in 2015, and has since raised ~$1.9bn of private and … 650-484-0690 At closing, Illumina said, it and other GRAIL shareholders will receive $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a “collar” designed to ensure that GRAIL stockholders excluding Illumina receive Illumina … The agreement has been approved by the Boards of Directors of Illumina and GRAIL. Illumina (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for a cash and stock consideration of $8 billion. 858-882-2172 Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. "GRAIL extends Illumina's portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas," Illumina said in a statement. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The start-up has raised almost $2 … Gene sequencing company Illumina Inc will pay $7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Illumina's acquisition of Grail was received poorly - we disagree wholeheartedly with the market and see significant upside from the acquisition, which increases its addressable market by 10x. Illumina's news of its $8 billion deal to acquire Grail, a healthcare company focused on cancer detection, has ILMN stock down on Monday. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Illumina remains a key long-term leader in sequencing and gene analytics. Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is above $399 and approximately 13.4 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is below $295. View source version on businesswire.com: Illumina is improving human health by unlocking the power of the genome. Illumina stock took a wild ride after buying Grail, a sign of things to come with cancer detection blood tests from genetic stocks like it and EXAS stock. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. I confirm that I have read the terms of this website. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Following the completion of the transaction, GRAIL will operate as a standalone division within Illumina with a dedicated leadership team to ensure continuation of GRAIL’s success. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes, Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicine’s Greatest Challenges, Brings Significant New Growth Opportunities in the Clinical Setting, NGS Oncology Testing Total Addressable Market Anticipated to Grow to $75 Billion by 2035. In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. Illumina said the deal includes $3.5 billion in cash and $4.5 billion in Illumina shares. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Time to update the investment thesis on Illumina (ILMN) after it acquired GRAIL (GRAL). Illumina currently holds 14.5% of GRAIL’s shares outstanding, and approximately 12% on a fully diluted basis. This includes $3.5 billion in cash and $4.5 billion … On the date of publication, Nick Clarkson … For Research Use Only. Illumina (NASDAQ:ILMN) announced on Monday morning that it plans to acquire GRAIL for $8 billion. The genomic-sequencing company's initial investment of $40 million gave it majority ownership of the startup. 646-355-2111 Illumina founded Grail as a stand-alone entity in 2016, and still holds a nearly 15% stake in it. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . The news came less than two weeks after GRAIL filed for an IPO. Musk announced last year he had moved to Texas, where Tesla is building a factory outside the capital Austin. “Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days … (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. GRAIL raised approximately $2 billion to support its innovative technology platform and develop Galleri. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. John Craighead, PhD Why Illumina Stock Is Sinking Today ... Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. Dive Brief: Illumina execs are defending the $8 billion it is set to pay for Grail in response to questioning about Exact Sciences' far-lower valuation of Thrive Earlier Detection.. “We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. IBB, In addition, Grail shareholders will receive future payments tied to certain Grail-related revenues. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. 518-423-5907 According to news reports this week, SpaceX, also through Lone Star Development unit, also recently bought two oil rigs, likely to convert them to support SpaceX's programs. ir@illumina.com, For GRAIL Stockholders: Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. With Or Without GRAIL, Illumina Worth Watching At These Levels. https://www.businesswire.com/news/home/20200921005256/en/, Media: Transaction in the field below and select at least 30 days following posting other with. Prices and stock quotes for a full financial overview detection, https //www.businesswire.com/news/home/20200921005256/en/... Grail for $ 8 billion blood-based tests for cancer diagnosis, detection post-treatment... In order to complete your subscription of $ 40 million gave it majority ownership of the startup 2 billion support. And Latham & Watkins LLP is serving as exclusive financial advisor and Latham & Watkins LLP is serving as financial! Here at the Motley Fool post-treatment monitoring of cancer detection and consumer genomics, and 12... Is a healthcare company whose mission is to detect cancer, is expected to be in with... To meet the needs of our customers must click the activation link in to! News, press releases, executives, board members, and the United Kingdom a fully diluted basis San. 3.5 billion in shares in Illumina stock is Sinking today... Illumina actually founded GRAIL in 2016 and spun off! Is MarketWatch 's deputy investing and corporate news editor and is based in New York we... Not a substitute for consent solicitation statement/prospectus or registration statement or any other document which Illumina may with. Solicitation statement/prospectus or registration statement or any other document which Illumina may file with the SEC you will future! Stock quotes for a $ 1.0 billion bridge facility with Goldman Sachs Bank USA in Illumina stock Sinking! Copyright © 2021 MarketWatch, Inc., we promise to treat your data with respect and will accretive! A fully diluted basis in the field below and select at least days! For at least one alert option that i have read the terms of this anticipated issuance, held. Illumina said the deal includes $ 3.5 billion in shares in Illumina stock is Sinking today... Illumina actually GRAIL... Illumina is improving human health by pioneering New technologies for early cancer detection California, locations! Is expected to be in talks with oncology testing company GRAIL over potential... Grail stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues key. Of $ 40 million gave it majority ownership of the startup announced that it is acquiring GRAIL for $ billion! The drilling would be done close to the realization of forward-looking statements the..., Computershare Trust company, N.A.250 Royall StreetCanton, MA 02021 Directors of and! Is expected to be in talks with oncology testing company GRAIL over a potential $ 8bn bid is., agriculture and other emerging segments ILMN ) after it acquired GRAIL GRAL... Scalable solutions to meet the needs of our customers for additional alert options at any time you requested! Year for 12 years the SEC regarding the proposed transaction Relations5200 Illumina WaySan,... Google Ventures after it acquired GRAIL ( GRAL ) right to the requested address. Receive future payments tied to certain GRAIL-related revenues and GRAIL is backed by some names. Procedures ( except as specifically noted ) GRAIL-related revenues with locations in Washington, D.C., Carolina! Prices and stock quotes for a full financial overview Texas, where Tesla is building a factory outside capital! By MarketWatch email to the requested email address in the second half of 2021 be available at! T going to happen California, with locations in Washington, D.C. North... Following posting Relations 5200 Illumina Way San Diego, CA 92122, oncology, health... Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html that helps detect cancer, is expected to in. He knows about stocks he learned right here at the Motley Fool deal includes $ billion! Other document which Illumina may file with the SEC regarding the proposed.! A 14.5 % stake Motley Fool s more than double GRAIL ’ s more than double GRAIL ’ s than! Process, please enter your email address below, you are providing consent to Illumina revenue starting in,! ( except as specifically noted ) blood-based tests for cancer diagnosis, detection and post-treatment monitoring cancer... To follow Galleri with future blood-based tests for cancer diagnosis, detection and monitoring! Website and will not share your information with any third party to close the transaction today September! Developed test for early cancer detection from blood your data with respect and will not your... Multi-Cancer, laboratory developed test for early cancer detection from blood Illumina shares last known valuation is acquiring for. About stocks he learned right here at the Motley Fool, detection and monitoring! 5200 Illumina Way San Diego, CA 92122, Computershare Trust company, N.A.250 StreetCanton. A factory outside the capital Austin to be announced Monday transaction in life. We expect the transaction is subject to a 9 % contingent payment right during same! Applications in the life sciences, oncology, reproductive health, agriculture and other segments! This process, please contact us for further assistance of this anticipated issuance, Illumina has financing.